New

CJC-1295 with DAC 5mg – long-acting GH stimulator

CJC-1295 (DAC) prolongs the growth hormone pulse, supporting protein synthesis, recovery and body composition. It is preferred for goals of lean mass/recomposition and in anti-aging strategies for tone and performance. It is often combined with Ipamorelin for GH synergy. Maximum results are achieved with sleep hygiene, sufficient protein and well-structured training.

0 reviews • Write a review

€ 40.00

Ex Tax: € 40.00

Qty

Add to Cart

Buy Now Question?

Add to Wish List

Ask a Question about this Product

Shipping

Secure and safe worldwide delivery! If the product is on stock - average delivery time is 2-3 days in Eastern Europe, 3-7 days in Western Europe and 1-3 weeks world wide!

Improved storage formula

Improved storage formula - increased stability and extended shelf life!

Quality Control & Tests

High-quality product! All peptides branded MyPeptid are produced in 100% laboratory conditions and have purity above 98%. Our products are tested at JINOSHIK, Analiza Białek and other independent, established laboratories with high standards!

Tags: Increase in GH/IGF-1

Product information

What is CJC-1295 with DAC?

CJC-1295 with DAC causes the body to release more of its growth hormone for a longer time, which changes how tissues are renewed and how energy stores are used.

In the hypothalamus–pituitary–liver axis regulation, GHRH analogs are tools for shaping the pulsatile secretion of growth hormone (GH) and the subsequent formation of IGF‑1. CJC-1295 with DAC is a modified GHRH(1–29) analog in which the DAC modification allows covalent binding to serum albumin and prolonged exposure compared with unmodified peptides. At the receptor level it activates the GHRH receptor in the adenohypophysis, enhancing cAMP‑dependent signaling and stimulating GH secretion; peripherally, the increased GH/IGF‑1 tone is used as a research tool to track anabolic, metabolic, and tissue‑remodeling effects.

Clinical and preclinical data

Study	Population/model	Number	Duration	Key observed outcomes
Phase I/IIa, placebo‑controlled (Teichman et al.)	Healthy adults	≈60	≈28–35 days	Sustained increase in IGF‑1 relative to baseline (approx. +50% to +100% depending on dose); the GH profile shows augmented pulsatile peaks without continuous secretion.

The available clinical data are limited in size and scope (short-term endpoints, mainly hormonal markers), which should be taken into account when planning validating experiments.

Pharmacokinetics and experiments

DAC‑mediated albumin binding is associated with an extended functional half‑life (approx. 6–8 days) and effects on IGF‑1 measurable up to about 10–14 days after administration. For laboratory protocols this means less frequent dosing in exposure models, but also a longer “washout” period in crossover designs, as well as the need for serial measurements (GH pulses and IGF‑1) for correct interpretation.

Research applications

CJC-1295 with DAC is used in translational models of the GH/IGF‑1 axis, metabolic physiology, sarcopenia and tissue repair, as well as in the development of analytical methods (LC‑MS/immunoassays) for long‑acting peptides. All described effects originate from controlled laboratory, preclinical, or clinical settings and are relevant for standardized comparison of biomarkers and signaling pathways.